TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01143376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity training
Description: high-intensity intermittent sprinting (HIIS) (8 sec sprint:12 sec rest) for 12 weeks, 4 times a week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: short springs
Description: short duration sprints (SDS)(8 sec sprint:12 sec rest) for 12 weeks, 4 times a week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity exercise
Study: NCT00880919

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quetiapine extended-release
Description: Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quetiapine extended-release
Description: Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
Study: NCT03774576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7017773
Description: Single doses of RO7017773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7017773
Description: Single doses of RO7017773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Multiple doses of Itraconazole
Study: NCT03439228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumbar brace
Description: 3 months of lumbar brace wear
Study: NCT02910882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGylated Recombinant Human Hyaluronidase (PEGPH20)
Description: PEGPH20 Dosing (Cohort I, Dose Escalation, First 3 patients): Administered as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute:~Dose level 1 - 1 mcg/kg; Dose level 2 - 1.6 mcg/kg; Dose level 3 - 3 mcg/kg.~PEGPH20 Dosing (Cohort II, Patients 4-10): Administered at a dose of 3 mcg/kg as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute.~Dosing Schedule: Twice per week beginning Day #1 for 8 doses, then weekly until end of radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine Dosing: Administered at a dose of 600 mg/m2 as an IV infusion over 30 - 60 minutes with standard antiemetic pre-medication. If administered on PEGPH20 day, Gemcitabine will be infused 2-4 Hours after PEGPH20 infusion is completed.~Dosing Schedule: Weekly, beginning Day #2, per standard regimen.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiotherapy, beginning Day #2, delivered at 1.8 Gy per fraction, 5 fractions per week (Monday - Friday), until a total dose of 50.4 to 54 Gy for up to 6 Weeks.
Study: NCT02815501

Intervention type: BIOLOGICAL
Intervention: blood samples
Description: for the determination of thyroid hormones (TSH, FT3, FT4 ) and antibodies against the thyroid (anti TPO antibodies and anti thyroglobulin)
Study: NCT02939287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1
Description: Add aprepitant to anti-emetic regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine10 mg orally daily on Days -1,0,+1 and +2
Description: add olanzapine to anti-emetic regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant plus Olanzapine
Description: add aprepitant and olanzapine to anti-emetic regimen
Study: NCT02191735

Intervention type: DEVICE
Intervention: RAMP 200
Description: The RAMP® Reader is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength at 560 nm and an emission wavelength of 610 nm. The RAMP® 200 is Response Biomedical's second generation reader. The RAMP® 200 is designed to process more tests with a smaller footprint.

Intervention type: DEVICE
Intervention: RAMP 200
Description: The RAMP® Reader is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength at 560 nm and an emission wavelength of 610 nm. The RAMP® 200 is Response Biomedical's second generation reader. The RAMP® 200 is designed to process more tests with a smaller footprint.

Intervention type: DEVICE
Intervention: RAMP 200
Description: The RAMP® Reader is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength at 560 nm and an emission wavelength of 610 nm. The RAMP® 200 is Response Biomedical's second generation reader. The RAMP® 200 is designed to process more tests with a smaller footprint.

Intervention type: DEVICE
Intervention: RAMP 200
Description: The RAMP® Reader is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength at 560 nm and an emission wavelength of 610 nm. The RAMP® 200 is Response Biomedical's second generation reader. The RAMP® 200 is designed to process more tests with a smaller footprint.

Intervention type: DEVICE
Intervention: RAMP Reader
Description: The RAMP® Reader is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength at 560 nm and an emission wavelength of 610 nm. The RAMP® Reader is Response Biomedical's first generation reader instrument. Designed for use at near-patient/bedside or locations such as: laboratories, hospitals, on-site Emergency Response and Emergency Rooms.

Intervention type: DEVICE
Intervention: RAMP Reader
Description: The RAMP® Reader is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength at 560 nm and an emission wavelength of 610 nm. The RAMP® Reader is Response Biomedical's first generation reader instrument. Designed for use at near-patient/bedside or locations such as: laboratories, hospitals, on-site Emergency Response and Emergency Rooms.
Study: NCT00329342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational ergonomic training
Description: Adequate postural habits in activities of daily living
Study: NCT02016456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-Burst Stimulation
Description: At 80% motor threshold determined using single pulse stimuli. Depending on the hemisphere determined by connectivity analysis and neuronavigation in each individual, either continuous (left prefrontal) or intermittent (right prefrontal) train of pulses will be delivered.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High frequency stimulation
Description: Left prefrontal stimulation. 120% motor threshold with a pulse sequence of 10 Hz for 4 seconds, followed by a 26 second quiet period. Treatment will last for a total of 37.5 minutes this is a total of 3,000 pulses
Study: NCT02101034

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study: NCT02191735

Intervention type: DEVICE
Intervention: RAMP Reader
Description: The RAMP® Reader is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength at 560 nm and an emission wavelength of 610 nm. The RAMP® Reader is Response Biomedical's first generation reader instrument. Designed for use at near-patient/bedside or locations such as: laboratories, hospitals, on-site Emergency Response and Emergency Rooms.

Intervention type: DEVICE
Intervention: RAMP Reader
Description: The RAMP® Reader is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength at 560 nm and an emission wavelength of 610 nm. The RAMP® Reader is Response Biomedical's first generation reader instrument. Designed for use at near-patient/bedside or locations such as: laboratories, hospitals, on-site Emergency Response and Emergency Rooms.
Study: NCT02101034

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332991
Study: NCT01681056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autosuggestion for 30 days
Study: NCT02253108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Everolimus eluting bioresorbable polymer stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biolimus eluting bioresorbable polymer stent
Study: NCT03336151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Front-of-pack labelling Nutri-Score
Description: Introduction of the Nutri-Score front-of-pack nutrition label on shelf display tags for every food and beverage sold in the cafeteria
Study: NCT04773496

Intervention type: DIAGNOSTIC_TEST
Intervention: instrumental description of the subject's center of gravity (COG) sway
Description: qualitative and quantitative analysis of the balance function through the description of the center of gravity (COG) sway
Study: NCT01907802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03225495

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard implant
Description: Arm - Standard Implant: implant placement in combination with guided bone regeneration;

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultra-narrow implant
Description: Arm - Ultra-narrow implant: implant placement without guided bone regeneration
Study: NCT03234790

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Filtered Air Exposure
Description: Exposure to Filtered air

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diesel Exhaust Exposure
Description: Diesel exposure to different concentrations at different times: 20, 50 and 150ug/m3
Study: NCT04517552

Intervention type: DRUG
Intervention: [11C]-CS1P1
Description: Participants will receive a single intravenous bolus injection of 6.0 - 20.0 mCi (222-740 MBq) of the investigational radiotracer \[11C\] CS1P1. Participants will then undergo a \[11C\] CS1P1 PET/CT scan.
Study: NCT00195858

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aerobic and resistance exercise
Description: aerobic and resistance exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aerobic and resistance exercise
Description: aerobic and resistance exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aerobic and resistance exercise
Description: aerobic and resistance exercise

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: aerobic and resistance exercise
Description: aerobic and resistance exercise
Study: NCT00861224

Intervention type: OTHER
Intervention: No Intervention for Observational Study
Description: No intervention was used on this protocol, as this was an observational study.
Study: NCT03057977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily
Study: NCT03207685

Intervention type: DEVICE
Group type: OTHER
Intervention: Additional Seizure Monitoring
Description: Embrace could offer an additional layer of seizure monitoring
Study: NCT02877563

Intervention type: OTHER
Intervention: Contrast ultrasound perfusion imaging of the limb
Description: Contrast enhanced ultrasound imaging at rest and during contractile exercise will be performed prior to revascularization and 3-4 weeks after revascularization.
Study: NCT03898947

Intervention type: PROCEDURE
Intervention: Diagnostic hysteroscopy and targeted endometrial biopsy
Description: Diagnostic hysteroscopy and targeted endometrial biopsy

Intervention type: PROCEDURE
Intervention: Diagnostic hysteroscopy and targeted endometrial biopsy
Description: Diagnostic hysteroscopy and targeted endometrial biopsy

Intervention type: PROCEDURE
Intervention: Diagnostic hysteroscopy and targeted endometrial biopsy
Description: Diagnostic hysteroscopy and targeted endometrial biopsy
Study: NCT04028882

Intervention type: OTHER
Intervention: Signaling, metabolomic and transcriptomic analysis
Description: Signaling, metabolomic and transcriptomic analysis
Study: NCT01399333

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Group 1 Meal Replacement
Description: 4 weeks of utilizing Group 1 Meal Replacement 3-4 times daily, supplementing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 Protein Supplement
Description: 4 weeks of utilizing Group 2 protein supplement 3-4 times daily, replacing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Group 3
Description: 4 weeks of utilizing Group 3 protein supplement 3-4 times daily, replacing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
Study: NCT01438684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RPh201
Description: 400 microliter s.c. twice a week for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 400 microliter Saline solution s.c. twice a week for 3 months
Study: NCT04616703

Intervention type: RADIATION
Intervention: CT imaging
Description: CT of abdomen

Intervention type: RADIATION
Intervention: CT imaging
Description: CT of abdomen

Intervention type: RADIATION
Intervention: CT imaging
Description: CT of abdomen
Study: NCT00995020

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Straight Wire Excision of Transformation Zone
Description: Straight wire excision of transformation zone is a electrosurgical conization method,which uses a straight wire electrode as a knife to remove the dysplastic epithelium of the cervix.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Large Loop Excision of Transformation Zone (cone biopsy)
Description: LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20-25 mm depth. The loop is applied to the cervix outside the lateral margin of TZ and brought slowly to the controlateral TZ margin.
Study: NCT04279938

Intervention type: DRUG
Group type: OTHER
Intervention: Tinostamustinein
Description: Tinostamustine80-120mg IV Q3W (dose to be determined in part 1) for 6 cycles

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg IV Q3W until disease progression or unacceptable toxicities (max. 2 years)

Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV Q3W for 6 cycles
Study: NCT02053038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iFR
Description: Treatment guided by instantaneous wave-free ratio

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FFR
Description: Treatment guided by Fractional Flow Reserve
Study: NCT04424797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone Positioning
Description: Intervention is patient in prone positioning

Intervention type: OTHER
Group type: OTHER
Intervention: Supine Positioning
Description: Intervention is patient in supine positioning
Study: NCT02530853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Description: Laser acupuncture

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Laser acupuncture
Description: Laser acupuncture
Study: NCT03325998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Samsung Hip Assist v1
Description: All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions. Each session is directed by a licensed physical therapist and lasted 60 min including rest period of 10 min. Brain activity and gait assessment is performed at visits 0 (baseline), 24 (post-test), and at 3 months (follow-up) after training.
Study: NCT00091117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT01121120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXA127
Description: 300mcg/kg/day, administered subcutaneously for up to 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 300mcg/kg/day administered subcutaneously for up to 28 days
Study: NCT00100854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Given intramuscularly
Study: NCT02271516

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 188Re-BMEDA-liposome
Description: EKG at baseline and in 24hours after administration
Study: NCT01658150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isradipine
Description: Isradipine is a medication that acts by blocking a specific type of receptor in the brain called a calcium channel
Study: NCT01902056

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One layer allograft
Description: The acellular dermal matrix was placed on the facial surface.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two layer allograft
Description: The acellular dermal matrix was placed on the facial surface.
Study: NCT03305354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBTI app intervention
Description: Self-management guided use of a mobile app called the CBT-I Coach to teach sleep hygiene and enhance sleep

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBTI app intervention
Description: Self-management guided use of a mobile app called the CBT-I Coach to teach sleep hygiene and enhance sleep

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity intervention
Description: Self-management guided motivation to increase physical activity by increasing daily step counts
Study: NCT01679795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tibolone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01924351

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Radiosurgery plus HER-2 directed therapy in HER2-positive Breast Cancer with Brain Metastasis
Study: NCT02918123

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FURESTEM-CD Inj.
Description: Patients will be treated FURESTEM-CD Inj. Subcutaneous injection
Study: NCT01206777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Dose 2 of Rituximab IVPB will be started at a rate of 100 mg/hr for the first 15 minutes. If tolerated, the remainder of the bag will be infused over 45 minutes.
Study: NCT02047292

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THA Corail PinnacleCoC28
Description: Uncemented THA with Corail stem and Pinnacle acetabular cup with CoC 28 mm head

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THA Corail DeltaMotion36
Description: Uncemented THA with Corail stem and DeltaMotion acetabular cup with 36 mm head

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THA Corail DeltaMotion40
Description: Uncemented THA with Corail stem and DeltaMotion acetabular cup with 40 mm head
Study: NCT04261335

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CL2020 cells
Description: 1.5 million or 15 million cells, IV on day 5 to 14 of birth
Study: NCT04510909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COMMIT mHealth application
Description: The investigators will develop Community-based mHealth Motivational Interviewing Tool (COMMIT) using iterative design and testing with frequent, structured input from the key stakeholders: community health workers (CHWs), their supervisors and adult depression patients.The tool will be used by community CHWs in Dolakha, Nepal to: 1) obtain decision-support to deliver motivational interviewing (MI) for patients in their communities, and 2) capture consented audio recordings of client interactions for review and feedback by their supervisors, allowing CHWs to maintain MI skills beyond the initial training period.
Study: NCT00440700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety Self-Management, Patient preferred relaxing music
Description: Experimental group randomized to patient-directed music intervention where subjects listened to tailored, self-selected music as desired (frequency and length determined by the individual subject) each day they are receiving mechanical ventilatory support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control 1: Noise-cancelling headphones
Description: Control group: noise-canceling headphones only where subjects wear headphones as desired (frequency and length determined by the individual subject) each day they are receiving mechanical ventilatory support.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control 2: Standard of Care
Description: Usual ICU nursing care.
Study: NCT01412463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stent placement
Description: * pre-dilation of the study lesion is mandatory~* stent placement with 1 Protégé Everflex+ stent~* only 1 stent is allowed within the study protocol~* post-dilation may be performed but is not mandatory
Study: NCT01838252

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: Hyaluronic acid filler will be injected in to the lower lid, elevating it to a more anatomic position

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Saline will be injected in to the lower lid, elevating it to a more anatomic position
Study: NCT01416688

Intervention type: PROCEDURE
Intervention: assessment of therapy complications
Description: Will be given by questionnaire

Intervention type: PROCEDURE
Intervention: psychosocial assessment and care
Description: Will be given by questionnaire

Intervention type: PROCEDURE
Intervention: quality-of-life assessment
Description: Will be given by questionnaire